All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
JCR, Alexion collaborate on genomic medicines using JUST-AAV
The JUST-AAV platform, which optimises adeno-associated virus (AAV) vectors for targeted delivery, will be used in five of Alexion’s programmes.
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.
KalVista secures FDA approval for Ekterly to treat HAE attacks
KalVista plans to launch Ekterly in the US immediately, allowing physicians to start prescribing the drug to treat HAE attacks.
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO and OSENVELT
STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S.
Chugai, Gero partner to develop therapies for age-related diseases
The collaboration will leverage Gero’s AI-driven platform for target discovery and Chugai’s antibody engineering technologies to create novel antibody drug candidates.
Biocon Biologics receives EC approval for Denosumab biosimilars
The biosimilars are designed to improve bone health by preventing complications and treating conditions such as osteoporosis and bone loss.
Brii Bio, Joincare sign licensing deal for BRII-693 in Greater China
Joincare will obtain rights to research, develop, and commercialise BRII-693 in Greater China, while Brii Bio retains the rights outside the territory.
NICE approves new drug for advanced bowel cancer patients in England and Wales
The drug will be available on the NHS within three months for specific patients with advanced bowel cancer, also known as stage 4 or metastatic bowel cancer, in England and Wales.
Neurizon signs licensing deal with Elanco to commercialise NUZ-001
NUZ-001 is an investigational therapy, currently under development for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases.
Regeneron secures FDA approval for Lynozyfic to treat multiple myeloma
Lynozyfic is a fully human BCMAxCD3 bispecific antibody, indicated for people who have undergone at least four prior lines of therapy.